Abstract 145P
Background
Glasgow prognostic score (GPS), which is defined with serum levels of two parameters, albumin >3.5 g/dl and C-reactive protein <1.0 mg/dl (both as 0, either as 1, and neither as 2), has a prognostic significance in various malignant solid tumors. In a small-scale retrospective study, GPS was useful as a prognostic factor for chemo-naïve advanced biliary tract cancer (ABTC) patients with good performance status (PS; defined with ECOG PS 0 and 1). We evaluated whether GPS was useful in large-scale prospective study for ABTC patients with good PS.
Methods
ABTC patients with PS 0/1 and not missing laboratory data among the patients who received gemcitabine + cisplatin (GC) or GC + S-1 (GCS) in a phase III study (MITSUBA) were analyzed for factors with P < 0.2, using multivariate Cox proportional hazards model for overall survival (OS). In the exploratory analysis, OS was compared between GC and GCS according to GPS.
Results
Clinical data were collected from 230 patients (113 patients in the GC arm and 117 patients in the GCS arm) among 241 patients. The proportion of patients was 43% in GPS 0, 35% in GPS 1, and 22% in GPS 2, respectively. In the univariate and multivariate analyses, GPS was an independent prognostic factor (hazard ratio [HR], 0.68; 95% confidence interval [CI], 0.56-0.81; P < 0.001). The median OS was 18.0 months (95%CI, 15.3-20.7), 12.6 months (95%CI, 11.4-13.8), and 7.2 (95%CI, 4.4-10.0) for patients with GPS 0, GPS 1, and GPS 2, respectively. The HRs of GCS to GC were 1.00 (95%CI, 0.64-1.55; P = 0.99), 0.72 (95%CI, 0.45-1.15; P = 0.17), and 0.57 (95%CI, 0.32-1.04; P = 0.07), for patients with GPS 0, GPS 1, and GPS 2, respectively.
Conclusions
GPS was useful for chemo-naïve ABTC patients with good PS, and GCS might improve OS, especially in patients with poor prognosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Kansai Hepato-Biliary Oncology Group.
Funding
Taiho Pharmaceutical.
Disclosure
T. Moriwaki: Speaker Bureau / Expert testimony: Taiho Pharmaceutical; Speaker Bureau / Expert testimony: Lilly. Y. Yamamoto: Speaker Bureau / Expert testimony: Taiho. T. Yamada: Advisory / Consultancy: Taiho; Speaker Bureau / Expert testimony: Lilly. A. Taketomi: Honoraria (institution), Leadership role: Taiho. K. Yoshimura: Honoraria (self): Taiho; Honoraria (self): Lilly; Honoraria (self): Nippon Kayaku. E. Hatano: Honoraria (self): Taiho; Honoraria (self), Advisory / Consultancy: Lilly. T. Ioka: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Taiho. All other authors have declared no conflicts of interest.
Resources from the same session
465P - A phase IIIb open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: Exploratory biomarker analysis
Presenter: Jie Wang
Session: Poster display session
Resources:
Abstract
470P - Prognostic significance of serum biomarkers in small cell lung cancer: A meta-analysis and systematic review
Presenter: Rogelio Velasco
Session: Poster display session
Resources:
Abstract
471P - Chemotherapy in advanced thymic malignancies
Presenter: Ankur Varshney
Session: Poster display session
Resources:
Abstract
466P - Cancer immunotherapy efficacy and patients’ age: A systematic review and meta-analysis
Presenter: Yu Jiang
Session: Poster display session
Resources:
Abstract
506P - Efficacy and safety of pegvorhyaluronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non-small cell lung cancer (NSCLC)
Presenter: Jeffrey Ward
Session: Poster display session
Resources:
Abstract
480P - Safety and efficacy of dacomitinib for EGFR+ NSCLC in the subgroup of Asian patients from ARCHER 1050
Presenter: Tony S.K. Mok
Session: Poster display session
Resources:
Abstract
503P - Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials
Presenter: Antonio Passaro
Session: Poster display session
Resources:
Abstract
488P - Randomized trial of prophylactic minocycline for erlotinib-associated skin rash in non-small cell lung cancer (PEARL trial)
Presenter: Kei Kusaka
Session: Poster display session
Resources:
Abstract
495P - Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
Presenter: Anna Buder
Session: Poster display session
Resources:
Abstract
520P - A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116)
Presenter: Akito Hata
Session: Poster display session
Resources:
Abstract